Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Harvard Business School
Citi
Merck
US Army
UBS

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,587,988

« Back to Dashboard

Which drugs does patent 7,587,988 protect, and when does it expire?

Patent 7,587,988 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in thirty-two countries.

Summary for Patent: 7,587,988
Title:Inhaler device counter
Abstract:Inhaler counter (20) comprising a counter housing (390), a rocker arm (200) with a pawl (210), the rocker arm being pivotally supported by the housing and arranged to perform a rocker movement in response to a linear actuation motion, a return spring (220) for resetting the rocker arm, a ratchet wheel (230) engagable with the pawl to convert the movement of the rocker arm into an incremental rotational motion of an axle arrangement (240) advancing a display means (60), the axle arrangement further comprising a back rotation prevention means (280) in the form of a spring loaded friction brake and a worm gear, the display means comprising rotatable indicator means (120) with teeth that engage the worm-gear and a stationary scale.
Inventor(s): Bowman; Nic (Cambridge, GB), Bradshaw; Douglas (Royston Herts, GB), Sorby; Lennart (Uppsala, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/570,747
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,587,988
Patent Claim Types:
see list of patent claims
Delivery; Use; Device;

Drugs Protected by US Patent 7,587,988

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,587,988

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0500857Apr 14, 2005
PCT Information
PCT FiledApril 10, 2006PCT Application Number:PCT/SE2006/000423
PCT Publication Date:October 19, 2006PCT Publication Number: WO2006/110080

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Moodys
Express Scripts
Boehringer Ingelheim
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.